ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "complement"

  • Abstract Number: 0608 • ACR Convergence 2024

    Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Chau-Ching Liu5, Nicole Wilson5, Susan Manzi5 and Tyler O'Malley6, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6Exagen, Vista, CA

    Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
  • Abstract Number: 2534 • ACR Convergence 2024

    Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics

    Juan Vargas1, Ian Mantel2, Jun Inamo3, Nirmal Banda1, Anna Helena Jonsson3, Kevin Wei4, Deepak Rao5, Susan Goodman6, Kevin Deane7, Jennifer Seifert8, Jennifer Anolik9, Michael Brenner10, Soumya Raychaudhuri11, Trent Woodruff12, the Accelerating Medicines Partnership (AMP) RA/SLE Network13, Michael Holers14, Laura Donlin15 and Fan Zhang16, 1The University of Colorado, Aurora, CO, 2WEILL CORNELL MEDICINE, New York, NY, 3University of Colorado School of Medicine, Aurora, CO, 4Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Hospital for Special Surgery, New York 10025, NY, 7University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 8University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 9University of Rochester Medical Center, Rochester, NY, 10Brigham Women's Hospital, Boston, MA, 11Brigham and Women's Hospital, Boston, MA, 12University of Queensland, Brisbane, Australia, 13AMP RA/SLE consortium, Aurora, CO, 14Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 15Hospital for Special Surgery, New York, NY, 16University of Colorado, Aurora, CO

    Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
  • Abstract Number: 0617 • ACR Convergence 2024

    Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation

    Clément triaille1, Neha Mohan Rao2, Gillian Rice3, Luis Seabra4, Sutherland Fraser5, Vincent Bondet6, Darragh duffy6, Andrew Gennery7, Benjamin Fournier8, Brigitte Bader-Meunier9, Christopher Troedson10, Gavin CLeary11, Helena Buso12, Jacqueline Dalby-Payne13, Ranade Prajakta14, Katrien Jansen15, Lien De Somer16, Marie-Louise Fremond17, Pimple Pallavi14, Melanie Wong18, Russel Dale10, Carine Wouters16, PIERRE QUARTIER19, Raju Khubchandani20 and Yanick Crow5, 1Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, 2NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, 3Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, 4Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France, Paris, France, 5MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, Edinburgh, United Kingdom, 6Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, 7: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom, 8Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, France, 9Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, 10T. Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, New South Wales, and University of Sydney, Australia, Sydney, Australia, 11: Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, Liverpool, United Kingdom, 12Department of Medicine - DIMED, University of Padova, Padova, Italy, Padova, Italy, 13Specialty of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Australia, Sydney, Australia, 14NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, India, 15Division of Pediatric Neurology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 16Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 17Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, United Kingdom, 18Department of Allergy and Immunology, Children's Hospital at Westmead, Westmead, Australia, Westmead, Australia, 19Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, 20SRCC Childrens Hospital, Mumbai, India

    Background/Purpose: To report on the largest cohort of C1Q deficient (C1QDef ) patients; to investigate the activation of Type 1 interferon pathway in the blood…
  • Abstract Number: 0629 • ACR Convergence 2024

    Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus

    Anca Askanase1, Edward Vital2, Oliver Meier3, Armando Turchetta4, Huiyan (Ashley) Mao4, Justine Maller5, Jorge A. Ross Terres6 and Maria Dall'Era7, 1Columbia University Medical Center, New York, NY, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc,, San Francisco, CA, 6Genentech, Inc,, San Francisco, 7UCSF, Corte Madera, CA

    Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
  • Abstract Number: 0669 • ACR Convergence 2024

    Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study

    buddhika Jayaratna1, Pasan Serasinghe2, Louise Nel3, Sahil Jain3, Shrish Sangle2, Begona Lopez1, Giovanni Sanna2, Michelle Fernando1 and David DCruz4, 1Guys & St Thomas NHS Foundation Trust, London, United Kingdom, 2Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, 3Guys and St Thomas' Hospital, London, United Kingdom, 4The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
  • Abstract Number: 1378 • ACR Convergence 2024

    Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis

    Marta Hernández-Díaz1, Iván Ferraz-Amaro2, Sergio Santos-Concepción3, Javier Castro3, Vanesa Hernandez4, Beatriz Tejera Segura5, Cristina Luna6, Esmeralda Delgado-Frías2 and Federico Diaz-González2, 1Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, 2Hospital Universitario de Canarias, La Laguna, Spain, 3Universidad de La Laguna, La Laguna, Spain, 4Rheumatology department. Hospital Universitario de Canarias, La Laguna, Spain, 5Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, 6Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz, Spain

    Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…
  • Abstract Number: 1490 • ACR Convergence 2024

    Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests

    Vasileios Kyttaris1, Andrew Concoff2, Touba Warsi3, Sepehr Taghavi3, Sudha Kumar3, Stanley Park3, Abigail Patalinghug3, Christine Schleif3, Brittany Partain4, Joseph Ahearn5, Nicole Wilson6, Chau-Ching Liu6, Susan Manzi6 and Tyler O'Malley7, 1BIDMC, Boston, MA, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Carlsbad, CA, 4Exagen, Boston, MA, 5Allegheny Health Network, Wexford, PA, 6Allegheny Health Network, Pittsburgh, PA, 7Exagen, Vista, CA

    Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
  • Abstract Number: 1607 • ACR Convergence 2024

    Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    Sebastian Klapa1, Sabrina Arnold2, Antje Müller2, Andreas Koch3, Anja Staehle4, Wataru Kähler3, Harry Heidecke5, Gabriela Riemekasten2 and Peter Lamprecht2, 1University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, 4University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany

    Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
  • Abstract Number: 1703 • ACR Convergence 2024

    Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure

    Rachael Wasikowski1, Erin Theisen2, Jie An3, Lam C. Tsoi1, Ksenia Anufrieva4, Kevin Wei5, Johann Gudjonsson6 and Keith Elkon3, 1Michigan, Dept. of Dermatology, Ann Arbor, MI, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 3University of Washington, Seattle, WA, 4BWH, Cambridge, MA, 5Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 6University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin sensitivity to sunlight affects ~70% of systemic lupus erythematosus (SLE). In addition, ultraviolet radiation (UVR) can stimulate systemic disease flares, but how this…
  • Abstract Number: 2065 • ACR Convergence 2024

    Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)

    Samantha Coss1, Danlei Zhou1, Rabheh Abdul Aziz2, Katherine Miller3, Shoghik Akoghlanian4, Kyla Driest1, Edward Oberle1, Vidya Sivaraman5, Charles Spencer6, Stacy Ardoin1 and Chack-Yung Yu7, 1Nationwide Children's Hospital, Columbus, OH, 2University at Buffalo, Buffalo, NY, 3Nationwide Children's Hospital, Institute for Genomic Medicine, Columbus, OH, 4Nationwide Children�s Hospital, Columbus, OH, 5Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 6University of Mississippi Medical Center, Jackson, MS, 7Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, OH

    Background/Purpose: JDM is an autoimmune disease of skin and muscle. We investigated genetic factors, autoantibodies, and clinical features in JDM.Methods: Subjects came from 2 large…
  • Abstract Number: 0040 • ACR Convergence 2024

    Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis

    Gary Sims1, Mia Collins2, Natalie Pursell3, Teneema Kuriakose1, Fanyi Jiang4, Kristi Moore5, Lucie Bertrand5, Melissa Lasaro5, Jessica Neisen6, Scott Manetz7, Gabriel Wong8, Patrick Riley5, Iain McInnes9, Kyriakos Konstantinidis10 and David Close8, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 3Dicerna, Lexington, 4Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 5Alexion, AstraZeneca Rare Disease, New Haven, CT, 6Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 7Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 8Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 9University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 10Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
  • Abstract Number: 2177 • ACR Convergence 2024

    CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients

    Dror Mevorach, Netanel Karbian, Marian Zeibak and Adi Tabib, Hadassah-University Hospital, Jerusalem, Israel

    Background/Purpose: We have described in 2013, homozygous CD59-deficient children that manifest with recurrent peripheral neuropathy resembling Guillain-Barré syndrome (GBS), with hemolytic anemia and recurrent strokes.…
  • Abstract Number: 0045 • ACR Convergence 2024

    Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins

    Khushali Trivedi1, Clarissa Klenke2, Jun Kim1, Jeba Atkia Maisha2, Alina Sememenko1, XIAOBO MENG2, Mario Navarrete1, Hani El-Gabalawy2 and Liam O'Neil2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
  • Abstract Number: 2230 • ACR Convergence 2024

    Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis

    Maria Garcia-Gonzalez1, Fuensanta Gomez-Bernal2, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
  • Abstract Number: 0114 • ACR Convergence 2024

    Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cécile Yelnik1, shruti chaturvedi2, Julien Labreuche3, Xiang-Zuo Pan2, H Michael Belmont4, Nina Kello5, Paul Fortin6, David Branch7, Yu Zuo8, Rohan Willis9, Robert Brodsky2, Jane Salmon10, Maria Laura Bertolaccini11, Hannah Cohen12, Michelle Petri13 and Doruk Erkan10, and on behalf of APS ACTION, 1lille university, Lille, France, 2John Hopkins University, Baltimore, MD, 3Lille University Hospital, Lille, France, 4NYU Langone Health, New York, NY, 5Northwell Health, Brooklyn, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7University of Utah and Intermountain Healthcare, Salt Lake City, UT, 8University of Michigan, Ann Arbor, MI, 9University of Texas Medical Branch, Galveston, TX, 10Hospital for Special Surgery, New York, NY, 11King's College London, London, United Kingdom, 12University College London Hospitals NHS Foundation Trust, London, United Kingdom, 13Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: We previously reported that markers of complement activation, specifically elevated C4d levels and positive modified HAM (mHAM) test, are associated with a higher risk…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology